- Important step for Tetra to ensure meaningful collaboration
and patient engagement in research.
OTTAWA, ON, July 22, 2021 /PRNewswire/ - Tetra
Bio-Pharma Inc. ("Tetra" or the "Company") (TSX: TBP)
(OTCQB: TBPMF) (FRA:JAM1), a leader in cannabinoid-derived drug
discovery and development announced today it has engaged
Christine Caron as Patient Partner
to support significant and active collaboration in research,
knowledge translation, and patient engagement within the pain and
Sepsis communities.
Guy Chamberland, CEO and Chief
Regulatory Officer of Tetra commented "We are very pleased to have
Ms. Caron join the Tetra team as its first Patient Partner.
Christine will provide valuable insights about living with
post-infection and pain, due to her amputations because of Sepsis,
that may validate or change the direction of concepts we explore,
such as targeting outcomes that are important to patients."
"Tetra is developing a patient centric approach to better
reflect patients' needs and preferences along its clinical
development programs. Tetra's drug products, such as QIXLEEF™, are
intended to improve pain management and quality of life, concepts
that are highly subjective and directly related to the patient's
reality. I'm grateful to Christine who willingly accepted to be our
first Patient Partner," commented Aurelia
De Pauw, Senior VP Clinical Programs/Medical Affairs.
Ms. Caron will be involved in reviewing and commenting on
informed consent forms, questionnaires, or interview guides related
to Tetra's clinical trials. She will also be assisting with
knowledge translation planning and with sharing Tetra's research
results with key audiences, such as the Amputee Coalition of
Canada, Sepsis Canada, Global
Sepsis Alliance, and Sepsis Alliance.
"We need to advocate and educate, because Sepsis does not
discriminate!" commented Ms. Caron. "I am thrilled to join Tetra in
the fight against Sepsis by contributing to advocacy, health
literacy, knowledge transfer, and to support families who share
this journey. I also believe in the therapeutic benefits of
cannabis and will advocate to bring safer pain management
prescription alternatives to patients".
About Christine Caron
In 2013, Ms. Caron lost multiple limbs after a dog bite sent her
into Septic Shock. Since then, she has been committed to raising
awareness about Sepsis and connecting with survivors and their
families. Christine has a strong professional background in
science and health communications, which has served her well in her
recent roles as Patient Advisor with the Canadian Sepsis
Foundation, Director on the Board of the Amputee Coalition of
Canada, and as a special guest
speaker at university level functions and multiple conferences on
Sepsis. You may learn more about Christine's story by visiting the
Global Sepsis Alliance page, here.
About Tetra Bio-Pharma
Tetra Bio-Pharma (TSX: TBP) (OTCQB: TBPMF) (FRA:JAM1) is
a leader in cannabinoid-derived drug discovery and development with
a FDA and a Health Canada cleared clinical program aimed at
bringing novel prescription drugs and treatments to patients and
their healthcare providers. Our evidence-based scientific approach
has enabled us to develop a pipeline of cannabinoid-based drug
products for a range of medical conditions, including pain,
inflammation, and oncology. With patients at the core of what we
do, Tetra Bio-Pharma is focused on providing rigorous scientific
validation and safety data required for inclusion into the existing
biopharma industry by regulators, physicians and insurance
companies.
For more information visit: www.tetrabiopharma.com
Neither the TSX Exchange nor its Regulation Services Provider
(as that term is defined in the policies of the TSX Exchange)
accepts responsibility for the adequacy or accuracy of this
release.
Forward-looking statements
Some statements in this
release may contain forward-looking information. All statements,
other than of historical fact, that address activities, events or
developments that the Company believes, expects or anticipates will
or may occur in the future (including, without limitation,
statements regarding potential acquisitions and financings) are
forward-looking statements. Forward-looking statements are
generally identifiable by use of the words "may", "will", "should",
"continue", "expect", "anticipate", "estimate", "believe",
"intend", "plan" or "project" or the negative of these words or
other variations on these words or comparable terminology.
Forward-looking statements are subject to a number of risks and
uncertainties, many of which are beyond the Company's ability to
control or predict, that may cause the actual results of the
Company to differ materially from those discussed in the
forward-looking statements. Factors that could cause actual results
or events to differ materially from current expectations include,
among other things, without limitation, the inability of the
Company to obtain sufficient financing to execute the Company's
business plan; competition; regulation and anticipated and
unanticipated costs and delays, the success of the Company's
research and development strategies, including the success of this
product or any other product, the applicability of the
discoveries made therein, the successful and timely completion and
uncertainties related to the regulatory process, the timing of
clinical trials, the timing and outcomes of regulatory or
intellectual property decisions and other risks disclosed in the
Company's public disclosure record on file with the relevant
securities regulatory authorities. Although the Company has
attempted to identify important factors that could cause actual
results or events to differ materially from those described in
forward-looking statements, there may be other factors that cause
results or events not to be as anticipated, estimated or intended.
Readers should not place undue reliance on forward-looking
statements. The forward-looking statements included in this news
release are made as of the date of this news release and the
Company does not undertake an obligation to publicly update such
forward-looking statements to reflect new information, subsequent
events or otherwise unless required by applicable securities
legislation.
View original content to download
multimedia:https://www.prnewswire.com/news-releases/tetra-bio-pharma-engages-christine-caron-as-patient-partner-301339458.html
SOURCE Tetra Bio-Pharma Inc.